OPKO Health, Inc. Share Price & Technical Analysis
OPK · $1.29 (+1.57%)
Healthcare / Diagnostics & Research
$1.29
+1.57%
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
18% return in May, 6% avg return in past 3 year May month.
2% return in 2026, 20% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | -8% | -8% | 18% | – | – | – | – | – | – | – | 2% |
| 25 | 0% | 13% | -6% | -18% | 8% | -7% | 0% | 17% | 7% | -7% | 0% | 0% | 8% |
| 24 | -33% | 0% | 20% | 0% | 17% | -14% | 17% | 21% | -12% | 0% | 0% | 0% | 15% |
| 23 | 0% | -15% | 36% | 0% | -7% | 57% | -14% | -5% | -16% | -25% | 25% | 0% | 37% |
| 22 | -35% | 0% | 10% | -21% | 11% | -17% | -4% | -4% | -14% | 0% | -21% | -20% | -115% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Overbought
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$838.15M
P/E ratio
—
52W high
$1.60
52W low
$0.98
Volume
24,43,509
Beta
1.41
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is OPKO Health, Inc. share price today?
- OPKO Health, Inc. (OPK) last traded around $1.29 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OPK have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OPK. Download the app for real-time alerts.
- How can I analyze OPKO Health, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.